D.A. Davidson & CO. decreased its position in Crispr Therapeutics AG (NASDAQ:CRSP) by 48.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,876 shares of the company’s stock after selling 7,375 shares during the quarter. D.A. Davidson & CO.’s holdings in Crispr Therapeutics were worth $349,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in the business. ARK Investment Management LLC increased its stake in Crispr Therapeutics by 211.2% in the 3rd quarter. ARK Investment Management LLC now owns 1,453,590 shares of the company’s stock worth $64,467,000 after acquiring an additional 986,450 shares during the last quarter. BlackRock Inc. increased its position in shares of Crispr Therapeutics by 19.6% during the 3rd quarter. BlackRock Inc. now owns 709,643 shares of the company’s stock valued at $31,471,000 after purchasing an additional 116,116 shares during the last quarter. Federated Investors Inc. PA bought a new position in shares of Crispr Therapeutics during the 2nd quarter valued at approximately $37,101,000. Credit Suisse AG increased its position in shares of Crispr Therapeutics by 56.0% during the 3rd quarter. Credit Suisse AG now owns 596,052 shares of the company’s stock valued at $26,435,000 after purchasing an additional 213,988 shares during the last quarter. Finally, Jennison Associates LLC bought a new position in shares of Crispr Therapeutics during the 3rd quarter valued at approximately $23,988,000. 43.88% of the stock is currently owned by institutional investors and hedge funds.

CRSP opened at $36.34 on Thursday. Crispr Therapeutics AG has a 52-week low of $17.40 and a 52-week high of $73.90.

Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Thursday, November 8th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.74) by ($0.33). Crispr Therapeutics had a negative net margin of 331.84% and a negative return on equity of 40.41%. The business had revenue of $0.56 million for the quarter, compared to analysts’ expectations of $2.64 million. During the same quarter in the previous year, the firm earned ($0.62) EPS. Crispr Therapeutics’s revenue was down 76.6% compared to the same quarter last year. Sell-side analysts anticipate that Crispr Therapeutics AG will post -3.26 earnings per share for the current fiscal year.

CRSP has been the topic of several analyst reports. Wells Fargo & Co initiated coverage on Crispr Therapeutics in a research report on Wednesday, October 10th. They set an “outperform” rating and a $65.00 target price on the stock. Zacks Investment Research raised Crispr Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, September 12th. BidaskClub downgraded Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, October 5th. Raymond James initiated coverage on Crispr Therapeutics in a research report on Thursday, September 20th. They set an “underperform” rating on the stock. Finally, Chardan Capital reissued a “buy” rating and set a $72.50 target price on shares of Crispr Therapeutics in a research report on Wednesday, August 8th. One research analyst has rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $62.42.

TRADEMARK VIOLATION WARNING: “D.A. Davidson & CO. Trims Holdings in Crispr Therapeutics AG (CRSP)” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/d-a-davidson-co-trims-holdings-in-crispr-therapeutics-ag-crsp/2664046.html.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.

Read More: Call Option

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Crispr Therapeutics AG (NASDAQ:CRSP).

Institutional Ownership by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.